Company Overview and News
The Hong Kong government is seeking to revive investor interest in offshore yuan bonds issued in the city by emphasising their role in helping to finance ventures related to the green economy and environmental sustainability.
BHKLY 55BC BNKHF 2388 CBQS
DUBAI, June 10 (Reuters) - Banking and property shares helped drive up Dubai’s stock market on Sunday, while the Qatari index fell on news that Commercial Bank’s talks to sell its stake in United Arab Bank (UAB) to a UAE investor had failed.
NMC 55BC CBQS
Higher earnings growth tends to coincide with valuation premiums, and Chinese equities are no exception. By nature of the country's fast-paced economic growth and the rising market capitalization of the Information Technology sector, China is among the highest-growth markets in the world. This broad-based high-growth trend is evident in the more than 20% long-term earnings growth estimates of Chinese indexes, as well as in price-to-earnings (P/E) ratio premiums compared to broad emerging markets and developed international indexes.
CHLKF 55BC MS.PRE MS.PRF MS.PRG MS.PRA CBQS CICHY 0941 MS.PRI CHL MS.PRK MS CICHF CCB 0939
DUBAI, June 7 (Reuters) - Banking shares dragged down Saudi Arabia’s stock market on Thursday on selling ahead of the Eid holiday, profit-taking also weighed on Dubai shares despite news of new economic stimulus steps.
Wang Dongsheng, male, Chinese ID No. 370602195611230414, former Director of Yantai Municipal Road Bureau, on suspicion of crime of taking bribes,fled to Australia with travel document numbered G46638056 on May 29, 2014. Possible location of current residence: Eastwood, Sydney, Australia.
0762 CHUFF 55BC CHU CBQS
Hong Kong’s stock market rose for a fifth straight session on Wednesday on the back of Nasdaq’s surge to another all-time high and Chinese telecoms company ZTE’s agreement to get the US ban lifted, extending gains in technology shares.
CHLLF 55BC SOTGY 2382 CBQS SNPTF AACAF CICHY 0700 CICHF AACAY CCB 0939
The recent death of a Chinese rural bank's chairman has put the spotlight on the troubles that small lenders in the country face as authorities clean up the financial sector in the world's second-largest economy.
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...